Caribou Biosciences, Inc. $CRBU Stock Holdings Raised by Renaissance Technologies LLC

Posted by Brian Himes on Aug 7th, 2026

Renaissance Technologies LLC lifted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) by 58.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,590,497 shares of the company’s stock after purchasing an additional 950,640 shares during the period. Renaissance Technologies LLC owned about 2.61% of Caribou Biosciences worth $4,922,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Millennium Management LLC increased its holdings in Caribou Biosciences by 107.4% in the third quarter. Millennium Management LLC now owns 3,216,535 shares of the company’s stock valued at $7,495,000 after buying an additional 1,665,946 shares during the last quarter. Marshall Wace LLP raised its stake in Caribou Biosciences by 600.2% during the fourth quarter. Marshall Wace LLP now owns 881,105 shares of the company’s stock valued at $1,401,000 after buying an additional 755,261 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Caribou Biosciences by 136.1% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 824,299 shares of the company’s stock worth $1,311,000 after buying an additional 475,216 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Caribou Biosciences by 741.6% during the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after buying an additional 463,391 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Caribou Biosciences by 319.6% in the 3rd quarter. XTX Topco Ltd now owns 441,541 shares of the company’s stock worth $1,029,000 after acquiring an additional 336,308 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Trading Up 1.9%

Shares of Caribou Biosciences stock opened at $1.64 on Friday. The business’s 50 day simple moving average is $1.75 and its 200-day simple moving average is $1.83. The stock has a market capitalization of $162.66 million, a price-to-earnings ratio of -1.15 and a beta of 2.38. Caribou Biosciences, Inc. has a twelve month low of $1.38 and a twelve month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The business had revenue of $2.40 million during the quarter, compared to analyst estimates of $2.21 million. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%. Sell-side analysts predict that Caribou Biosciences, Inc. will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright boosted their price target on Caribou Biosciences from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Caribou Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Read Our Latest Report on CRBU

Caribou Biosciences Company Profile

(Free Report)

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.